HomeLatest ThreadsGreatest ThreadsForums & GroupsMy SubscriptionsMy Posts
DU Home » Latest Threads » n2doc » Journal
Introducing Discussionist: A new forum by the creators of DU
Page: 1 2 3 4 5 6 ... 922 Next »


Profile Information

Gender: Do not display
Home country: USA
Current location: Georgia
Member since: Tue Feb 10, 2004, 12:08 PM
Number of posts: 34,017

About Me

Environmental Scientist

Journal Archives

Why dentists are speaking out about the plastic beads in your toothpaste

By Abby PhillipThe tiny plastic beads found in many popular toothpaste brands are approved by regulators, but dentists are becoming increasingly alarmed that the beads could cause more dental hygiene problems than they solve.

Polyethylene plastic beads became all the rage in personal care products -- including toothpastes, face washes and body scrubs -- a few years ago. And the Food and Drug Administration says they're safe.

But the beads do not disintegrate and are not biodegradable, and dentists are concerned that they're getting suck in the tiny crevices of teeth.

"They’ll trap bacteria in the gums which leads to gingivitis, and over time that infection moves from the gum into the bone that holds your teeth, and that becomes periodontal disease," dentist Justin Phillip said, according to Phoenix ABC affiliate KNXV. "Periodontal disease is scary.”

The beads are similar to the slightly larger exfoliating beads the Illinois legislature banned this year because the products can't be sifted out of the water supply and can end up in large bodies of water, where they can harm marine life.


This is Stunning: Greenland's Black Snow

By Eric Holthaus
Jason Box knows ice. That’s why what’s happened this year concerns him so much.

Box just returned from a trip to Greenland. Right now, the ice there is … black:

The ice in Greenland this year isn’t just a little dark—it’s record-setting dark. Box says he’s never seen anything like it. I spoke to Box by phone earlier this month, just days after he returned from his summer field research campaign.

“I was just stunned, really,” Box told me.

The photos he took this summer in Greenland are frightening. But their implications are even more so. Just like black cars are hotter to the touch than white ones on sunny summer days, dark ice melts much more quickly.

As a member of the Geological Survey of Denmark and Greenland, Box travels to Greenland from his home in Copenhagen to track down the source of the soot that’s speeding up the glaciers’ disappearance. He aptly calls his crowdfunded scientific survey Dark Snow.



Thursday TOON Roundup 4- The Rest








Thursday TOON Roundup 3- Politics

Thursday Toon Roundup 2- Goodell Must Go

Thursday Toon Roundup 1: We got the War

Hepatitis C drug in India to cost 2% of US Price

NEW DELHI: Sofosbuvir, the wonder medicine for Hepatitis C that costs $84,000 or Rs 50.4 lakh for a 24-week treatment regimen in the US, will soon be available in India for about $1,800 or roughly Rs 1.1 lakh for the same regimen. The patent holder, pharma major Gilead, announced on Monday that it would be selling the drug at this price in India and also giving voluntary licences to seven Indian pharma companies to produce it.

The voluntary licencing deal promises to make the drug cheap in Indias as well as up to 91 countries where the Indian firms are allowed to sell it. But this has come at the cost of these Indian companies agreeing to abandon India's partners in its fight against Big Pharma for access to inexpensive medicines — Brazil, Russia, China, Thailand and many other middle-income countries. The Indian manufacturers will not be allowed to sell sofosbuvir in these countries.

Under the licensing agreement Cadila Healthcare, Cipla, Hetero Labs, Mylan Laboratories, Ranbaxy Laboratories, Sequent Scientific and Strides Arcolab have the right to develop and market generic versions of sofosbuvir and a related drug, ledipasvir, in 91 developing countries.

"We believe in the capabilities of our partner companies for high quality, low cost, high volume manufacturing. The competition between them will bring down the price of the generic version of sofosbuvir and thus this partnership will help bring about better access to patients globally. Gilead will have no control over their pricing. Our partner companies will set their own prices," said Greg H Alton, executive vice president of Gilead, at a press conference.



Wednesday Toon Roundup 5- The Rest







Wednesday Toon Roundup 4-GOP

Wednesday Toon Roundup 3- Inevitable

Go to Page: 1 2 3 4 5 6 ... 922 Next »